Halozyme Therapeutics Inc [HALO] stock is trading at $57.65, up 0.87%. In order to assess the stock’s recent performance, you can check whether its short-term value is rising or falling. The HALO shares have gain 6.33% over the last week, with a monthly amount glided 7.06%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, Morgan Stanley downgraded its rating to Equal-Weight on May 14, 2025, and kept the price target unchanged to $62. On May 13, 2025, downgrade downgraded it’s rating to Underperform but maintained its price target of $47 on the stock. Wells Fargo downgraded its rating to a Equal Weight and increased its price target to $62 on October 07, 2024. JP Morgan downgraded its rating to a Neutral and raised its price target to $57 on September 19, 2024. Piper Sandler downgraded its rating to Neutral for this stock on June 07, 2024, and upped its price target to $51. In a note dated February 29, 2024, TD Cowen initiated an Outperform rating and provided a target price of $54 on this stock.
Halozyme Therapeutics Inc [HALO] stock has fluctuated between $42.01 and $70.50 over the past year. Currently, Wall Street analysts expect the stock to reach $62 within the next 12 months. Halozyme Therapeutics Inc [NASDAQ: HALO] shares were valued at $57.65 at the most recent close of the market. An investor can expect a potential return of 7.55% based on the average HALO price forecast.
Analyzing the HALO fundamentals
Halozyme Therapeutics Inc [NASDAQ:HALO] reported sales of 1.08B for the trailing twelve months, which represents a growth of 35.22%. Gross Profit Margin for this corporation currently stands at 0.82% with Operating Profit Margin at 0.55%, Pretax Profit Margin comes in at 0.56%, and Net Profit Margin reading is 0.45%. To continue investigating profitability, this company’s Return on Assets is posted at 0.22, Equity is 1.22 and Total Capital is 0.29. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of3.13.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 57.16 points at the first support level, and at 56.67 for the second support level. However, for the 1st resistance point, the stock is sitting at 58.14, and for the 2nd resistance point, it is at 58.63.
Ratios To Look Out For
For context, Halozyme Therapeutics Inc’s Current Ratio is 8.39. In addition, the Quick Ratio stands at 7.30 and the Cash Ratio stands at 1.17. Considering the valuation of this stock, the price to sales ratio is 6.55, the price to book ratio is 14.72 and price to earnings (TTM) ratio is 15.30.
Transactions by insiders
Recent insider trading involved Torley Helen, PRESIDENT AND CEO, that happened on Jul 10 ’25 when 20000.0 shares were sold. PRESIDENT AND CEO, Torley Helen completed a deal on Jul 09 ’25 to sell 20000.0 shares. Meanwhile, PRESIDENT AND CEO Torley Helen sold 20000.0 shares on Jul 08 ’25.
